AMENDMENTS TO THE CLAIMS

The following listing of the claims replaces all prior claims presented in the application.

1-13. (Cancelled)

14. (Currently amended) A method for inhibiting ~~the~~ accumulation of ~~an~~ amyloid β peptide ~~or fragment thereof~~ in the brain, comprising the step of administering to a subject in need of such inhibition a[[n]] _free-end specific_ antibody which is targeted to an amyloid β peptide, ~~or to fragment thereof, thereby inhibiting~~ _to inhibit_ the accumulation of said amyloid β peptide ~~or fragment thereof~~ in the brain of said subject.

15-18. (Cancelled)

19. (Original) The method of claim 14, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

20. (Currently amended) A method for inhibiting the neurotoxicity of amyloid β peptide ~~or fragment thereof~~, comprising the step of administering to a subject in need of such inhibition a[[n]] _free-end specific_ antibody which is targeted to _an_ amyloid β peptide, ~~or fragment thereof, thereby inhibiting~~ _to inhibit_ the neurotoxicity of amyloid β peptide ~~or fragment thereof~~ in said subject.

21-24. (Cancelled)

25. (Original) The method of claim 20, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

26-50. (Cancelled)

51. (Currently amended) The method of claim 14, wherein the antibody is ~~free-end specific and~~ targeted to the free N-terminus of amyloid β-peptide ~~or a fragment thereof~~.

52. (Currently amended) The method of claim 20, wherein the antibody is ~~free-end specific and~~ targeted to the free N-terminus of amyloid β-peptide ~~or a fragment thereof~~.

53-54. (Cancelled)

55. (Currently amended) The method of claim [[14]] 51, wherein the antibody is a monoclonal antibody ~~free-end-specific and is~~ targeted to the free N-terminus of amyloid β-peptide ~~or a fragment thereof~~, wherein the first amino acid of said N-terminus is aspartate at position 1 of amyloid β-peptide.

56. (Currently amended) The method of claim [[20]] 52, wherein the antibody is ~~free-end-specific and is~~ a monoclonal antibody targeted to the free N-terminus of amyloid β-peptide ~~or a fragment thereof~~, wherein the first amino acid of said N-terminus is aspartate at position 1 of amyloid β-peptide.

57-58. (Cancelled)

59. (Currently amended) The method of claim 14, wherein the antibody is targeted to the free C-terminus of amyloid β-peptide ~~free-end-specific and targeted to a free N-terminus of an amyloid β-peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini~~.

60. (Currently amended) The method of claim 20, wherein the antibody is targeted to the free C-terminus of amyloid β-peptide ~~free-end-specific and targeted to a free N-terminus of an amyloid β-peptide fragment truncated at the C-terminus, N-terminus or both the N- and C-termini~~.

61-62. (Cancelled)

63. (Currently amended) The method of claim [[14]] 59, wherein the antibody is ~~free-end-specific and~~ a monoclonal antibody targeted to the free C-terminus of the amyloid β-peptide Aβ1-39, Aβ1-40, Aβ1-41, Aβ1-42 or Aβ1-43.

64. (Currently amended) The method of claim [[20] 60, wherein the antibody is ~~free-end-specific and~~ a monoclonal antibody targeted to the free C-terminus of the amyloid β-peptide Aβ1-39, Aβ1-40, Aβ1-41, Aβ1-42 or Aβ1-43.

65-70. (Cancelled)

71. (Currently amended) The method of claim [[14]] 63, wherein the antibody is ~~free-end-specific and is~~ targeted to the free C-terminus of the amyloid β- peptide ~~Aβ1-42~~ Aβ1-40, Aβ1-41, Aβ1-42 or Aβ1-43.

72. (Currently amended) The method of claim [[20]] 71, wherein the antibody is ~~free-end-specific and is~~ targeted to the free C-terminus of the amyloid β- peptide ~~Aβ1-42~~ Aβ1-40.

73. (New) The method of claim 71, wherein the antibody is targeted to the free C-terminus of the amyloid β- peptide Aβ1-42.

74. (New) The method of claim 64, wherein the antibody is targeted to the free C-terminus of the amyloid β- peptide Aβ1-40, Aβ1-41, Aβ1-42 or Aβ1-43.

75. (New) The method of claim 74, wherein the antibody is targeted to the free C-terminus of the amyloid β- peptide Aβ1-40.

76. (New) The method of claim 74, wherein the antibody is targeted to the free C-terminus of the amyloid β- peptide Aβ1-42.

77. (New) A method for inhibiting accumulation of amyloid β peptide in the brain, comprising the step of administering to a subject in need of such inhibition a free-end specific antibody which is targeted to an amyloid β peptide fragment truncated at position 3, 11 or 17, to inhibit the accumulation of said amyloid β peptide in the brain of said subject.

78. (New) The method of claim 77 wherein said free-end specific antibody is specific for an amyloid β peptide fragment that begins with a pyroglutamate residue at position 3.

79. (New) The method of claim 77 wherein said free-end specific antibody is specific for an amyloid β peptide fragment that begins with a pyroglutamate residue at position 11.

80. (New) The method of claim 77, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

81. (New) The method of claim 77, wherein the antibody is targeted to the free N-terminus of said amyloid β-peptide fragment.

82. (New) The method of claim 77, wherein the antibody is targeted to the free C-terminus of said amyloid β-peptide fragment.

83. (New) A method for inhibiting the neurotoxicity of amyloid β peptide, comprising the step of administering to a subject in need of such inhibition a free-end specific antibody which is targeted to an amyloid β peptide fragment truncated at position 3, 11 or 17, to inhibit the neurotoxicity of amyloid β in said subject.

84. (New) The method of claim 83 wherein said free-end specific antibody is specific for an amyloid β peptide fragment that begins with a pyroglutamate residue at position 3.

85. (New) The method of claim 83 wherein said free-end specific antibody is specific for an amyloid β peptide fragment that begins with a pyroglutamate residue at position 11.

86. (New) The method of claim 83, wherein the antibody is a monoclonal antibody, a humanized antibody, a chimeric antibody, a bispecific antibody, an artificial antibody, a scFv antibody or a F(ab), or fragment thereof.

87. (New) The method of claim 83, wherein the antibody is targeted to the free N-terminus of said amyloid β-peptide fragment.

88. (New) The method of claim 83, wherein the antibody is targeted to the free C-terminus of said amyloid β-peptide fragment.

89. (New) A method for inhibiting accumulation of amyloid β peptide in the brain, which comprises administering to a subject in need of such inhibition a free-end specific antibody which is targeted to an amyloid β peptide.

90. (New) A method for inhibiting the neurotoxicity of amyloid β peptide, which comprises administering to a subject in need of such inhibition a free-end specific antibody which is targeted to an amyloid β peptide.

91. (New) A method for inhibiting accumulation of amyloid β peptide in the brain, which comprises administering to a subject in need of such inhibition a free-end specific antibody which is targeted to an amyloid β peptide fragment truncated at position 3, 11 or 17.

92. (New) A method for inhibiting the neurotoxicity of amyloid β peptide, which comprises administering to a subject in need of such inhibition a free-end specific antibody targeted to an amyloid β peptide fragment truncated at position 3, 11 or 17.